Roche drops third partnership deal
This article was originally published in Scrip
Executive Summary
Roche subsidiary Genentech has terminated a collaboration with Seattle Genetics for dacetuzumab (SGN-40), a monoclonal antibody targeting CD40 which is in Phase Ib testing for the treatment of non-Hodgkin's lymphoma and multiple myeloma.